Introduction
The serine/threonine protein kinase B/Akt (PKB) acts downstream of the phosphoinositide 3-kinase (PI3K) and functions as an essential mediator in many growth-factor-induced cellular responses including metabolism, proliferation and cell survival. 1, 2 In unstimulated cells, PKB/Akt resides within the cytosol in a catalytically inactive state. Activation of PI3K by growth factors leads to generation of phosphatidylinositol (3, 4, 5) trisphosphate (PtdIns(3,4,5)P 3 ) which recruits inactive PKB/Akt to the plasma membrane. The full activation of PKB/Akt requires both the phosphorylation of Thr 308 by phosphoinositidedependent protein kinase-1 (PDK1) and the phosphorylation of Ser 473 in the hydrophobic motif. 3, 4 Once activated, PKB/Akt phosphorylates and modulates the activity of several downstream targets in the cytoplasm and nucleus. Akt-mediated phosphorylation of the proapoptotic Bcl-2 family member BAD, 5 caspase 9, 6 and apoptosis signal-regulated kinase 1 (Ask1) 7 inhibits their proapoptotic function. In nuclei, Akt both negatively regulates Forkhead family of transcription factors that promote the expression of death genes 8 and positively regulates cAMP-response element-binding protein transcription factors that induce survival genes. 9 Akt counteracts the effect of cyclindependent kinase inhibitors on cell cycle progression by modulating their intracellular localization and level of transcription. 10 Overexpression of constitutively activated Akt mutants in many cell types promotes cellular transformation by stimulating proliferation and inhibiting apoptosis, and constitutive Akt activation has been observed in cancer cells as the result of Akt amplification and mutation in protein components of PI3-kinase signaling cascade. 11 Human leukemia HL-60 cells have been extensively studied as an experimental model of the biochemical mechanisms specific to differentiation pathways. All-trans-retinoic acid (ATRA) and dimethyl sulfoxide (DMSO) induce maturation of HL-60 toward cells carrying some granulocytic markers and phorbol 12-myristate 13-acetate (PMA) causes the cells to differentiate into a macrophage-like phenotype. Although ATRA is known to act primarily through the RAR/RXR nuclear receptors, several studies demonstrated the activation of enzymes related to the phosphoinositide signaling pathway in the nuclei of ATRA-differentiated HL-60 cells. 12, 13 Class I PI3K activity responsible for the production of PtdIns(3,4,5)P 3 was detected to be bound to nuclear matrices during the ATRAinduced granulocytic differentiation, 14 the ATRA-induced activation of nuclear class I enzymes was mediated by interaction of p85 and Vav adapter, 15 and the granulocytic differentiation was inhibited by either wortmannin or the antisense fragment of p85a. 16 Although the presence of PKC-z in nuclei of ATRAdifferentiated HL-60 cells has been described, 17 the putative activation of other PI3K-downstream targets in nuclei of differentiated cells, including Akt/PKB, has not been investigated. Recently, the role of PI3K/Akt-pathway has been extensively investigated in HL-60 cell clone (HL60AR, for apoptosis resistant) with a constitutively activated PI3K/Akt axis due to an autocrine production of insulin-like growth factor-1. [18] [19] [20] [21] The analysis of the subcellular distribution of Ser 473 p-Akt in HL-60 parental cells and HL60AR-line with a constitutively active PI3K/Akt-pathway show that the increase in the level of phosphorylated Akt is mostly due to the increase in the level of the nuclear enzyme. 18 These HL-60AR cells are resistant not only to chemotherapeutic agents but also to granulocytic differentiation induced by ATRA. 19 The pharmacological inhibitors of PI3K/Akt pathway have been proposed in the treatment of leukemia based on the inhibitory effects of these compounds on growth factordependent malignant cell proliferation. However, if the nuclear PI3K/Akt is involved in ATRA-mediated differentiation, it is possible that PI3K/Akt inhibitors may block the antitumor properties of retinoids in vivo. The aim of the present study was to investigate the possible activation of nuclear Akt in ATRA-treated cells and the effects of new, selective Aktinhibitors on ATRA-mediated differentiation.
Materials and methods

Chemicals and reagents
Reagents were obtained from the following sources: insulin, DMSO, PMA, ethylene glycol-bis (2-aminoethylether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA), Tris, leupeptin, phenylmethylsulfonyl fluoride, Triton X-100, sodium dodecyl sulfate (SDS), color markers, bovine serum albumin (BSA), propidium iodide, RNase A from Sigma (St Louis, MO, USA); fetal bovine serum (FBS) from Gibco, Invitrogen, UK; ATRA, 1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate (Akt inhibitor I), D-3-deoxy-2-O-methyl-myo-inositol 1-((R)-2-methoxy-3-(octadecyloxy)propyl hydrogen phosphate) (SH-5, Akt inhibitor II), LY 294002, PD 98059 from Calbiochem, La Jolla, CA, USA; enhanced chemiluminescent substrate for detection of HRP from Pierce, USA. Mouse monoclonals to tubulin was purchased from Sigma, rabbit polyclonals to lamin from Santa Cruz Biotechnology, and rabbit polyclonals to total and phosphospecific (phospho-Ser 473 , phospho-Thr 308 ) Akt, rabbit polyclonals to total and phospho-specific (phospho-Thr 202 /Tyr 204 ) p44/ 42 MAP kinase, and secondary antibodies conjugated to horseradish peroxidase were purchased from Cell Signaling Technology (Beverly, MA, USA). FITC-conjugated monoclonal antibodies (MoAbs) to CD11b and FITC-conjugated isotypic control were purchased from Becton Dickinson, Immunocytometry Systems (San Jose, CA, USA). Small interfering RNA (siRNA) SMARTpool Akt1 was purchased from DharmaconUpstate, (Lafayette, CO, USA) and fluorescein-labeled negative control siRNA from Qiagen (Valencia, CA, USA). All other chemicals were of analytical grade.
Cell culture, cell differentiation and flow cytometric analysis HL-60 cells (ECCACC no. 88112501) were obtained from the European Collection of Animal Cell cultures, PHLS, Porton, Salisbury, UK. NB4 cells were kindly provided by Dr M Golemovic (Clinical Hospital Zagreb, Croatia). The cells were maintained in exponential growth in RPMI 1640 medium with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 mg/ml streptomycin in 5% CO 2 humidified atmosphere at 371C. For cell differentiation, the cells in the logarithmic growth phase were harvested by centrifugation and resuspended in a fresh medium containing 10% FBS. The cells were seeded at an initial cell density of 2.0-2.5 Â 10 5 /ml in six-well plates (Nunc, Roskilde, Denmark) in the presence of 1 mM ATRA or vehicle alone. At day 2, 0.3 ml of fresh medium was added to each well. In some cases, Akt inhibitor I (1L-6-hydroxymethyl-chiroinositol 2(R)-2-O-methyl-3-O-octadecylcarbonate), Akt inhibitor II (SH-5), LY 294002 and PD 98059 were added to the cultures at the times and concentrations indicated in the figure legends.
Cell growth was quantified using a hemocytometer. Viable cells were determined by trypan blue exclusion. The surface expression of CD11b, or binding of FITC-conjugated mouse IgG1 was determined by flow cytometric analysis as previously described. 22 For each marker, a total of 15 000 events were Preparation of postnuclear membranes was achieved by centrifugation of supernatant, which remained above the cushion after nuclear fraction was obtained. The supernatant was diluted in STM buffer to give final concentration of 162 mM sucrose and spun at 106 000 g for 90 min at 41C in a Beckman SW 28.1 rotor. The resultant pellet was considered to contain postnuclear membranes.
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Isolation of cytosolic fraction
Cytosolic fraction was prepared by homogenization of the cells in a small volume of STM buffer containing all inhibitors as described above. The homogenates were spun at 106 000 g for 90 min at 41C in a Beckman SW 28.1 rotor. The clear supernatant was considered to be cytosolic fraction.
Preparation of total cell lysates
To obtain homogenates, cells were washed with ice-cold PBS and resuspended in lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin). PMSF (1 mM) and microcystin (1 mM) were added to the lysis buffer immediately before use. After 10 min, the cells were homogenized by seven passages through a 23-gauge needle and incubated on ice for an additional 10 min. At the end of incubation, insoluble materials were removed by centrifugation at 14 000 g for 10 min.
Akt activity assay
Akt was immunoprecipitated from nuclei, postnuclear membranes, cytosolic fraction and total cell lysates, and its activity was assayed using the Crosstide peptide (GRPRTSSFAEG) as a substrate. 24 Immunoprecipitates were incubated with 30 ml of kinase assay mixture (50 mM Tris, pH 7.5, 0,1% (v/v) 2-mercaptoethanol, 0.1 mM EGTA, 17 mM PKI (PKA inhibitor peptide TTYADFIASGRTGRRNAIHD), 50 mM Crosstide, 167 mM [g 32 P]-ATP (Amersham, specific activity of 500 000 cpm/mol) and 16.7 mM MgAc. After incubation for 10 min at 301C under continuous shaking, reaction was stopped by pipetting 40 ml of the assay mixture onto a phosphocellulose paper. Papers were washed five times with 0.5% (v/v) phosphoric acid, once with acetone, dried and analyzed by liquid scintillation counting.
Western blot analysis
Equal amounts of proteins from cell lysate (100-200 mg) or nuclear fraction (70-100 mg) were boiled for 5 min in SDS polyacrylamide gel electrophoresis (PAGE) sample buffer. After a brief centrifugation, samples were resolved by electrophoresis using a Bio-Rad Minigel apparatus at an acrylamide concentration of 8% (v/w). After electrophoresis, the proteins were transferred onto nitrocellulose membranes using a Bio-Rad wet-blotting system. Nonspecific binding was inhibited by incubation in TBST (25 mM Tris, 0.15 M NaCl, pH 8.0, with 0.1% Tween 20) containing 5% nonfat dry milk for 1 h at room temperature. Primary polyclonal rabbit antibodies against Akt, phospho-Akt (Ser 473), phospho-Akt (Thr 308), and phosphoThr 202 /Tyr 204 ) p44/42 MAP kinase were diluted in TBST containing 5% BSA (1:1000) and incubated overnight at 41C. The blots were washed three times with TBST and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies diluted (1:2000) in TBST containing 5% nonfat dry milk for 1-3 h at room temperature. Visualization was carried out using the ECL kit.
RNA interference assays
Exponentially growing HL-60 cells were transfected with siRNA SMARTpool Akt1 or fluorescein-labeled nonsilencing duplex siRNA using electroporation procedure, with an ElectroSquarePorator apparatus (Genetronics Inc, San Diego, CA, USA), according to the manufacturer's protocols. Briefly, siRNA (2.72 nmol) in siRNA buffer was mixed with 10 Â 10 6 cells in 500 ml of RPMI plus 20% FBS. Following electroporation, cells were allowed to recover in 3 ml of RPMI culture medium with 20% FBS. After 24 h, cells transfected with fluorescein-labeled siRNA were subjected to cytofluorimetric analysis to determine transfection efficiency. Cells transfected with silencing siRNA were treated with ATRA and subjected to Western blot analysis and evaluation of the expression of CD11b.
Statistical analysis
Results are shown as means7s.e.m. The two-tailed Student's t-test was used to compare different groups. Values with Po0.05 were considered significant.
Results
To allow differentiation along granulocytic pathway, HL-60 or NB4 cells were incubated in the presence of 1 mM ATRA for 4 days. At the end of incubation, an aliquot of cells was analyzed by flow cytometry to confirm the increase in the expression of differentiation marker, and the rest of the sample was used to isolate total cell lysates, nuclei or other subcellular fractions. To assess the possible activation of nuclear Akt in ATRA-differentiated cells, nuclei and total cell lysates were resolved on SDS-PAGE, transferred to nitrocelullose, and the membranes were incubated with a phospho-specific antibody that detects Akt only when phosphorylated on serine 473. Insulin is known to support proliferation and survival of HL-60 cells in the absence of serum, and has been reported to stimulate Akt in different cell types.
1,2 Thus, total cell lysates of HL-60 cells that were starved for 24 h prior to stimulation with insulin for 10 min were used as a positive control. As shown in Figure 1a , an increase in the level of the phosphorylated Akt was detected in total cell lysates of insulin-treated and ATRA-differentiated HL-60 cells. The level of phosphorylated Akt was higher in control NB4 cells and further increased in the presence of ATRA. In isolated nuclei, an increase in the level of Ser 473 p-Akt was detected after 96 h of ATRA treatment. To further demonstrate that Akt is activated in nuclei of ATRA-treated cells, Akt was immunoprecipitated from whole-cell lysates and nuclei, and the kinase activity of precipitated Akt was examined by in vitro The role of Akt in HL-60 cells K Matkovic et al kinase assays using Crosstide as a substrate. The in vitro kinase activity of Akt was found to be increased in total cell lysates of insulin-treated and ATRA-differentiated cells and in the nuclei isolated from ATRA-treated cells (Figure 1b ). To further demonstrate that the observed changes in the level of Aktactivity in ATRA-differentiated HL-60 cells occur predominantly in the nuclei and are not due to an increase in the activity of the enzyme in other subcellular compartments, postnuclear membranes and cytosolic fractions were isolated from either control cells or cells treated with ATRA for 96 h. As shown in Figure 2 , the kinase assay show no increase in the activity of Akt immunoprecipitated from either postnuclear membranes or cytosol.
Time-course study of the nuclear Akt activity revealed a progressive increase in the levels of both total and Thr 308 and Ser 473 phosphorylated Akt that correlated well with the increase in the activity of Akt immunoprecipitated from the nuclei of ATRA-differentiated HL-60 cells and the increase in the expression of CD11b marker (Figure 3) . In contrast, when the same samples were probed with antibodies specific for total p44/42 MAP kinase and the Thr 202 /Tyr 204 phosphorylated form, an increase in the level of the total enzyme was accompanied with a parallel decrease in the level of Thr 202 /Tyr 204 phosphorylated enzyme. In NB4 cells, the kinase assay show a progressive increase in the activity of Akt immunoprecipitated from the nuclei of ATRA-treated cells that reached a peak 72 h after the addition of ATRA (Figure 3d ).
To test for the possibility that the increase in the level of nuclear Akt activity reflects cellular changes during differentiation that are common to all granulocytic inducers and/or inducers with a strong antiproliferative effect, HL-60 cells were treated for 5 days with DMSO that is known to induce the expression of granulocytic markers, and PMA that has a strong To test for the role of the Akt activation in ATRA-mediated differentiation, the expression of Akt protein was downmodulated by using commercially available siRNA sequences. As shown in Figure 5a , transfection of HL-60 cells with siRNA targeted against Akt reduced the amount of Akt protein in both control and ATRA-treated cells. The decrease in the amount of protein was associated with a significant decrease in the level of CD11b expression in cells treated with ATRA for 72 and 96 h (Figure 5b) .
Previous studies have shown that in HL-60AR cells, with a constitutively active PI3K/Akt axis, the Akt inhibitor I (1L-6-hydroxy-methyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate) did not significantly affect PI3K activity up to a concentration of 20 mM, while at the same final concentration inhibited approximately 73% of Akt activity. 20 To test the effects of the inhibitor on ATRA-mediated differentiation, the Akt inhibitor I (20 mM) was added to HL-60 cells either 30 min before addition of 1 mM ATRA or at 48 h after the addition of ATRA, and the number of viable cells were counted daily up to 96 h. As shown in Figure 6 , the presence of Akt inhibitor I did not prevent the growth arrest induced by ATRA. On the contrary, both the number of ATRA-treated and control cells were strongly reduced by the presence of the Akt inhibitor I. Furthermore, the presence of the Akt inhibitor I had no inhibitory effects on the ATRAmediated increase in the level of CD11b. Moreover, the presence of the Akt inhibitor alone induced a small, but significant increase in the binding of anti-CD11b in control cells (with no increase in the binding of a relevant isotypic control). To further test for the effects of Akt-inhibition, another Akt inhibitor (Akt-inhibitor II or SH-5) was applied in doses that were previously shown to be effective in several cell types. 25, 26 As shown in Figure 6 , the effects of 10 mM Akt-inhibitor II on the growth and the expression of CD11b in both control and ATRAtreated cells were similar to the effects of 20 mM Akt inhibitor I, and the effects of 20 mM Akt-inhibitor II were even more pronounced.
Before the synthesis of new pharmacological Akt-inhibitors, PI-3K inhibitor LY 294002 has been widely used to study the role of PI3K/Akt pathway. LY 294002 at a final concentration of 10 mM has been previously shown to effectively reduce both PI3K and Akt activities in HL-60AR cells, 20 and the presence of wortmannin, the another, less stable PI3K inhibitor was previously reported to inhibit ATRA-induced activation of nuclear PI3K and granulocytic differentiation. 16 Thus, the effects of LY 294002 on ATRA-mediated differentiation were further investigated. As shown in Figure 7 , the effect of PI3K inhibitor on the cell number was similar to the presence of Akt-inhibitors, but the effects on the expression of CD11b were different; the presence of LY 294002 significantly reduced the percentage of cells expressing the surface markers in response to ATRA, while having no stimulatory effects on the expression of CD11b in control cells. Figure 4 The expression of surface markers and the activity of immunoprecipitated Akt in nuclei isolated from HL-60 cells treated with DMSO, PMA, and ATRA. HL-60 cells were incubated in the presence of one of the following agents: 1.25% vol/vol DMSO (5 days), 500 nM PMA (3 days), or 1 mM ATRA (4 days). After the incubation, an aliquot of cells was analyzed by flow cytometry for the expression of surface marker (a). The rest of the sample was used to isolate nuclei, nuclear Akt was immunoprecipitated and the kinase assays were performed using Crosstide as a substrate (b). *Po0.05 (Student's t-test) with respect to the control. 
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To exclude the possibility that the difference in the response of our HL-60 cells to PI3K and Akt-inhibitors was due to some possible unknown specificity of the particular cell line used, we tested the effects of MEK-inhibitor PD98059 that is known to reduce both proliferation and differentiation of HL-60 cells in response to ATRA. 27 As shown in Figure 7 , the presence of 20 mM PD98059 alone did not induce differentiation markers, but inhibited the appearance of ATRA-induced CD11b positive cells, and reduces the rates of cell proliferation in both control and ATRA-treated cells, as previously described. 27 To further confirm that the treatment with Akt-inhibitors resulted in Akt-inhibition, the Akt-activity was measured in nuclei isolated after the treatment with different inhibitors. As shown in Figure 8a , there was a gradual decrease in the level of nuclear Akt-activity that correlated well with the effect of Akt inhibitors on growth and CD11b expression. The Western blot analysis of total cell lysates showed that the treatment with Akt inhibitor II decreased the level of the Akt phosphorylation (Figure 8b) . NB4 cell line, established from an APL patient, shows the typical t(15;17) chromosomal translocation, expresses the PML/RAR fusion protein, and is sensitive to ATRA-induced cell differentiation. 28 As shown in both Figures 9 and 10 , the basal level of CD11b expression in control NB4 cells was much higher than the level observed in HL-60 cells, and the maximal increase in the CD11b expression was observed early after exposure to ATRA. Therefore, the effects of inhibitors on ATRAmediated differentiation were investigated at 48-96 h after the addition of ATRA. The presence of Akt inhibitor I (20 mM) had no effects on the percentage of both control and ATRA-treated cells expressing differentiation markers and had no significant effects on cell growth. The addition of Akt inhibitor II at the higher doses (20 mM) was shown to be toxic to the NB4 cells within 48 h. When Akt II inhibitor was applied at a lower dose (10 mM) that showed an inhibitory effect on the number of viable control (Figure 10) . However, the effects of Akt inhibitors on the level of CD11b expression in control cells (Figure 9 ) differed from the effects of LY 294002 and MEKinhibitor PD98059 (Figure 10 ).
Discussion
As a number of tumoral processes have been correlated with constitutively high Akt activity, it has been proposed that the selective Akt pharmacological inhibitors might be used in the future for enhancing sensitivity of leukemia cells to cytotoxic drugs, ionizing radiation or ATRA. 11, 20 Although the enhanced Akt is usually associated with the proliferative and survival signal in leukemia cells, G-CSF-induced signal in myeloid cells is associated with enhanced Akt and differentiative, not proliferative, responses. 29 In various cell culture systems, PI3K-Akt signaling has been implicated as a critical pathway for the differentiation of chondrocytes, osteoblasts, and osteoclasts. 30, 31 Activation of the PI3K/Akt pathway by retinoic acid is required for neural differentiation of neuroblastoma cells, 32 and Akt2 localizes to the nucleus of the differentiated myoblasts and plays a specific role in the commitment of myoblasts to differentiation. 33 The level and the activity of PI3K, the major upstream regulator of Akt, has been found to progressively increase in the nuclei of ATRA-treated HL-60 cells, 14, 15 and the presence of wortmannin, a PI3K inhibitor, prevented ATRAmediated antiproliferative and differentiative effects. 16 Thus, there is a possibility that the combined treatment of leukemia cells with retinoid and newly synthesized Akt-inhibitors would interfere with retinoid-induced differentiation and growth inhibition.
The results of the present study show that the level of the nuclear Akt, measured by both the level of the enzyme protein phosphorylated at Ser and Thr residues, and the kinase activity in the assay using Crosstide as a substrate, increases in HL-60 cells after 96 h of ATRA-treatment. The increase in the Aktactivity observed by both methods in total cell lysates is probably due to the high nuclear/cytoplasmic ratio in HL-60 cells, as no increase in the level of the activity was observed in other cellular compartments, including cytosolic fraction and postnuclear membranes. The increase in the level of the phosphorylated Akt parallel the increase in the PI3K level that was previously described in the nuclei of ATRA-treated cells, 14 and both corresponded to the appearance of the differentiated phenotype.
14, 16 The nuclear Akt activation does not seem to be a common effect of all agonists that induce the appearance of the CD11b surface marker and G 0 -arrest in HL-60 cells as no significant increase in the kinase activity was observed in PMA and DMSO-treated cells at the end of the usual incubation period. 13 However, the increase in the Akt-activity is not restricted only to HL-60 cells in response to the treatment with ATRA. In acute promyelocytic NB4 line, in which ATRA induces the activation of the p70 S6 kinase, the increase in the level of Ser-phosphorylated Akt was described in lysates after 24 and 48 h of ATRA-treatment. 34 The results of our study show an increase in Akt-activity in both total cell lysates and nuclei isolated from NB4 cells at 96 h after the addition of ATRA and a progressive increase in the Akt-activity in nuclei isolated from ATRA-treated NB4 cells, reaching a peak at 72 h. The activation of several signaling pathways have been identified previously as targets of retinoids action, in addition to the induction of formation of RAR/RXR complexes, and some of them play roles in the generation of ATRA effects. 35 In order to test whether the activation of nuclear Akt in ATRA-treated cells need to increase for differentiation to proceed or whether the increase is only a consequence of differentiation, the effects of down-modulation of the expression of Akt were further investigated. Results show that a decrease in the level of Akt-protein is followed by a decrease in the expression of CD11b in ATRA-treated cells, which is in agreement with previous data showing that either down-modulation of p85 by antisense fragment 16 or Vav adapter by siRNA 36 inhibited the granulocytic differentiation. Akt inhibitor I and Akt inhibitor II (SH-5) are phosphatidylinositol ether lipid (PIA) analogues that cannot be phosphorylated by PI3K on the 3-position of the myo-inositol ring, but bind to the PH domain of Akt, thus acting as competitive inhibitors for Akt activation. 37, 38 NB4 cells are promyelocytic cells that display the PML-RARa-encoding t (15, 17) translocation that is specific for AML-M3. HL-60 cells are myeloblastic cells isolated from AML-M2 patient that are different from AML-M3 blasts but share the responsiveness to ATRA and are widely used to demonstrate the differentiative activity of ATRA and to predict its in vivo efficiency. Results of our study showed that the known effects of PI3K and MEK-inhibitors were similar in both cell lines. However, the effects of the Akt inhibitor II were different. In NB4 cells, that were shown to have higher basal levels of Aktactivity, CD11b-expression and sensitivity to the presence of the Akt II inhibitor, the ATRA-induced expression of CD11b was inhibited similar to the effects of LY 294002, although having no inhibitory effects on the expression of the marker in control In contrast, when Akt inhibitor I was applied at a dose that was previously shown to restore the sensitivity of HL60AR cells to chemotherapeutic drugs, TRAIL, ATRA, and ionizing radiation, 20 and Akt inhibitor II in a dose that was previously shown to effectively inhibit the Akt activity in different cell types, 25, 26 no inhibitory effects were observed on ATRA-induced expression of CD11b in HL-60 cells. The presence of either Akt inhibitor I or Akt inhibitor II significantly reduced the number of viable control and ATRA-treated HL-60 cells, Akt II inhibitor being more effective than Akt I inhibitor, as previously described. 26 Besides inducing cytotoxicity in control HL-60 cells, the presence of Akt inhibitors induced a dose-dependent increase in the percentage of control cells expressing CD11b. There is a possibility that the effect of Akt inhibitors is to promote maturation of the surviving cells along the granulocytic lineage, as shown for TRAIL, that induced not only a rapid cytotoxicity in HL-60 cells, but also increased the expression of CD11b through a caspase-dependent pathway. 39 Another possibility is that the small percentage of HL-60 cells that initially expressed the CD11b is somehow more resistant to the cytotoxic effects of Akt inhibitors. In contrast, neither PI3K inhibitor LY 294002 nor MEK inhibitor PD98059 induced any granulocytic maturation in control cells, although both inhibitors exerted the antiproliferative effect on both control and ATRA-treated cells similar to the one observed in the presence of Akt inhibitors. Furthermore, both LY 294002 and PD98059 had a different effect on the expression of CD11b in ATRA-treated cells, inhibiting the expression to the level similar to the one previously described. 27 The major conclusion is that the presence of Akt inhibitors inhibited the growth of both control and ATRA-treated HL-60 cells, while having no inhibitory effects at all on ATRA-mediated differentiation. Since these effects are in contrast with the effect of down-modulating expression of Akt-protein in the same cell line, and differ from the effect of inhibitors on ATRA-mediated expression in NB4 cells, the effects can be attributed to some other target molecules that are influenced by the pharmacological inhibitor in HL-60 cell line.
In conclusion, the data from the present study have shown that the activity of the nuclear Akt increases in ATRAdifferentiated HL-60 and NB4 cells, and that the downmodulation of the expression of Akt protein in HL-60 cells reduces the CD11b expression in ATRA-treated cells. The treatment of both cell lines with the commercially available Akt inhibitors inhibited the growth of both control and ATRAtreated cells. Akt-inhibitors had no inhibitory effects on ATRAmediated growth arrest and the expression of CD11b in HL-60 cells, but increased the percentage of control cells expressing 
